echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui set up a new company in the field of antivirals.

    Hengrui set up a new company in the field of antivirals.

    • Last Update: 2020-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    1, Hengrui and Sun Yang, the establishment of a new company July 6, Jiangsu Hengrui Pharmaceuticals announced that the subsidiary Shanghai Hengrui Pharmaceutical Co., Ltd. invested 60 million yuan, associated with natural persons, the company's actual controller Mr. Sun Yiyang invested 40 million yuan, jointly set up a new company.
    announced that Shanghai Hengrui and Sun Weiyang jointly funded the establishment of ReillyDi (Shanghai) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Reedi"), with a registered capital of 100 million yuan.
    scope of business shall be technology development, technical consulting, technical services and technology transfer in the field of biomedicine (except for projects subject to approval in accordance with the law, the business activities shall be carried out independently in accordance with the law on the basis of business licenses).
    understood that Rydy is responsible for antiviral therapy research and development, production, sales and related import and export business.
    antiviral drugs are the company's new areas, this transaction is conducive to the company to enrich the product line, is an important part of the company's development strategy, to improve product structure, improve product market competitiveness has a long-term impact.
    , Hengrui Pharmaceuticals is one of the well-known research and production bases of anti-tumor drugs, surgical drugs and virulents.
    company's products cover anti-tumor drugs, surgical anesthesia drugs, special infusions, contrast agents, cardiovascular drugs and many other fields, has formed a relatively complete product layout, including anti-tumor, surgical anesthesia, contrast agents and other areas of market share in the industry.
    face this march into the field of antivirals? 2, in recent years, a number of new subsidiaries Since 2018, Hengrui has added Shandong Shengdi Pharmaceutical, Fujian Shengdi Pharmaceutical, Ruishi Bio, Jiangsu original drug research and development subsidiaries, the main business includes chemical and biological drug research and development, commercial entities, drug research and development.
    , Hengrui as China's pharmaceutical industry leading enterprises, the core advantage is research and development and marketing two aspects.
    e.g. in research and development: after the innovation drug "project - research and development - listing - sales" of the full cycle, in which Apatini as the iconic product, since 2018, formed the peak of the market for innovative drugs, which is also its short-term sustained growth guarantee.
    2019 Rema zolund, karelli pearl monoanti, 2018 pyridoxine, 19K, 2014 Apatinistinist, these innovative drugs several new adaptives have entered Phase III clinical, short-term is in a high outbreak period.
    especially Karelli pearl single resistance, Hengrui domestic clinical is not weaker than BMS and MSD, the future peak revenue is expected to reach 15 billion yuan.
    , pipeline has 40 innovative drugs in the clinical stage, forming a number of new drugs declared IND every year, every year there is a virtuous development cycle of innovative drugs NDA.
    addition, it has maintained high investment in research and development, and continues to improve.
    From 2011 to 2019, Hengrui's research and development expenditure increased from 400 million yuan to 3.9 billion yuan, and its share of revenue rose from 8.79 percent to 16.73 percent.
    in marketing, Hengrui has established an academic promotion team of more than 10,000 people, and based on the original market experience to innovate ideas, establish a branch sales force, strengthen the depth and breadth of marketing.
    2018, the company established a product line division, at the company level set up a cancer division, imaging division, integrated products, surgical anesthesia division.
    this, the company's dositasi, Ilidakang and other exclusive varieties of the market share are stable in the forefront, especially in the field of surgical anesthesia and shadow agents, the competitive advantage is more obvious.
    the core strengths of both are directly reflected in Hengrui's performance.
    's 2019 annual report shows that the company achieved operating income of RMB23,289 million during the reporting period, up 33.70% from the same period last year, and net profit attributable to the owners of the parent company was RMB5.328 billion, up 31.05% from the same period last year.
    3, the antiviral market, $56.4 billion viral diseases are currently one of the major threats to human health, especially the new coronavirus pneumonia outbreak, making antivirals a hot area.
    analysis, common human viral infections include influenza, AIDS, hepatitis B, hepatitis C, rabies and so on.
    2019, the global antiviral drug market reached $56.4 billion, with a four-year compound growth rate of 8.23 percent, according to Grand View Research.
    , the total market for TOP10 for antiviral drugs worldwide is $27 billion, about half the size of the entire antiviral market.
    but in the global antiviral drug TOP10, there are 8 anti-HIV drugs, hepatitis C drugs have 2, the sales of these two types of drugs are also basically 80% and 20%.
    (Photo Source: New Kangjie) In fact, under the monopoly of the global anti-HIV drug oligopoly, several new drugs on the market for composite oral drugs have rewritten the rankings.
    In 2018, the global market for anti-HIV drugs has reached $34 billion, with a compound annual growth rate of more than 8%, top15's anti-HIV drug market has reached more than $24 billion, new drugs are growing faster, and products are ups and downs in the market.
    overall, there has been steady growth, with the global anti-HIV market expected to exceed $45 billion by 2023.
    In addition, in 2018, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal systemic antiviral drug market reached 19,089 million yuan, an increase of 9.01% year-on-year, China's urban public hospitals occupy an important position.
    background, the State Drug Administration has also accelerated the introduction of new drugs for imported and domestically produced anti-regenerative immunodeficiency syndrome through a series of policies, which is a major step forward in antiviral treatment in China.
    the promotion of medical insurance policy, as well as new compound, long-acting drugs for clinical characteristics, antiviral drugs hospital market will usher in rapid development.
    , the new crown epidemic still exists, some drug research and development enterprises with the support of policies to actively lay out and accelerate research and development.
    pharmaceutical companies to join the anti-viral new drug research and development camp.
    Hengrui into the field of antivirals, the specific deep cultivation of which aspect, we do not know, but Hengrui management's vision, so that Hengrui can always be a step faster - whether it is the early selection of high-end generic drug exports, or cancer innovative drugs, Hengrui has entered the hot track as fast as possible, the future Hengrui will be how layout, Cypress Blue will remain concerned.
    original title: Hengrui has a new action!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.